Key facts for NCD 230.19
- Benefit category
- Drugs and Biologicals
- Effective date
- 06/19/2006
- Implemented 06/19/2006
- Transmittal
- Transmittal 48
- Versions published
- 2
- Manual section
- 230
- Renal and Genitourinary System - ESRD Services, NCD Manual (Pub. 100-03) chapter 1 part 4
TL;DR
NCD 230.19 sets Medicare's national policy for levocarnitine for use in the treatment of carnitine deficiency in esrd patients under the benefit category "Drugs and Biologicals", effective 06/19/2006 and implemented 06/19/2006. Intravenous levocarnitine, for one of the following indications, will only be covered for those ESRD patients who have been on dialysis for a minimum of three months. It has been revised 1 time since publication and binds every Medicare Administrative Contractor nationally.
Item or service described
CIM 45-32
Carnitine is a naturally occurring substance that functions in the transport of long-chain fatty acids for energy production by the body. Deficiency can occur due to a congenital defect in synthesis or utilization, or from dialysis. The causes of carnitine deficiency in hemodialysis patients include dialytic loss, reduced renal synthesis and reduced dietary intake.
Indications and limitations of coverage
Intravenous levocarnitine, for one of the following indications, will only be covered for those ESRD patients who have been on dialysis for a minimum of three months.
Patients must have documented carnitine deficiency, defined as a plasma free carnitine level
• Erythropoietin-resistant anemia (persistent hematocrit
Continued use of levocarnitine will not be covered if improvement has not been demonstrated within 6 months of initiation of treatment. All other indications for levocarnitine are non-covered in the ESRD population.
For a patient currently receiving intravenous levocarnitine, Medicare will cover continued treatment if:
• Levocarnitine has been administered to treat erythropoietin-resistent anemia (persistent hematocrit
Text reproduced from the CMS Medicare Coverage Database record for NCD 230.19 version 2. View the original on cms.gov.
Local policies that build on this NCD
1 active Local Coverage Determination cites NCD 230.19 among its related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.
- Assays for Vitamins and Metabolic Function (L34914) · Novitas Solutions, Inc.
How MACs bill NCD 230.19
A National Coverage Determination states the policy; the Medicare Administrative Contractors publish the articles that turn it into claim edits. 1 current article in the Medicare Coverage Database names NCD 230.19, 1 of them with a covered ICD-10-CM list, from 1 contractor. The lists can differ by contractor even though the NCD is national, because each MAC codes the policy for its own claims system; check the article of the contractor that processes the claim.
| Contractor | Articles |
|---|---|
| Novitas Solutions, Inc. | A56416 |
A56416: Billing and Coding: Assays for Vitamins and Metabolic Function
Billing and Coding, effective 2026-10-01 · Novitas Solutions, Inc. (04111, 04112, 04211, 04212, 04311, 04312, 04411, 04412, 04911, 07101, 07102, 07201, 07202, 07301, 07302, 12101, 12102, 12201, 12202, 12301, 12302, 12401, 12402, 12501, 12502, 12901) · CMS record
900 covered ICD-10-CM codes in 7 groups; 10 procedure codes: 82306, 82379, 82607, 82652, 82746, 83090, 83698, 84207, 85385, 86352. Local policy: L34914 Assays for Vitamins and Metabolic Function. Check a diagnosis for 82306.
First covered codes: A15.0 Tuberculosis of lung; A15.4 Tuberculosis of intrathoracic lymph nodes; A15.5 Tuberculosis of larynx, trachea and bronchus; A15.6 Tuberculous pleurisy; A15.7 Primary respiratory tuberculosis; A15.8 Other respiratory tuberculosis; …
Coverage analysis history
CMS opens a national coverage analysis (NCA) to create or reconsider an NCD; the analysis carries a CAG tracking number, the evidence review and the decision memo. The Medicare Coverage Database links one analysis to NCD 230.19, listed here in the order CMS opened them (by NCA record number). A reconsideration ("Recon") revisits an earlier decision; an analysis whose status is open is still in progress.
- CAG-00077N Levocarnitine for End Stage Renal Disease (New, Closed)
Revision history
03/2006 - Correct typegraphical errors from conversion of CIM to NCD. Effective and implementation dates 06/19/2006. ( TN 48 ) (CR4278)
11/2002 - Implemented National Coverage Determination for Levocarnitine for End Stage Renal Disease under §1862(a)(1)(A) of the Social Security Act. Effective and implementation dates 01/01/2003. ( TN 162 ) (CR 2438)
How this NCD shows up on remittances
A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.
For teams evaluating QuickIntell software
Evaluate a coverage-review workflow around NCD 230.19
Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions — NCD 230.19
What does NCD 230.19 cover?
Intravenous levocarnitine, for one of the following indications, will only be covered for those ESRD patients who have been on dialysis for a minimum of three months. The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.
When did NCD 230.19 take effect?
The current version (2) is effective 06/19/2006, implemented 06/19/2006, published in transmittal 48. CMS lists 2 versions of this NCD.
Does a Local Coverage Determination override NCD 230.19?
No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database NCDs via the CMS Coverage APIVersion API snapshot 2026-09-27 · effective 2026-09-20 · file national-coverage-ncd.jsonSHA-256 a90fadfd264b9ef4…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- Medicare Coverage Database national coverage analyses (NCA/CAL report) via the CMS Coverage APIVersion API snapshot 2026-11-16 · effective 2026-11-16 · file national-coverage-ncacal.jsonSHA-256 563369a07b95140a…
Disclaimer
This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.